Research graph
References from First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Unresolved reference
External reference
Ebola haemorrhagic fever in Zaire, 1976
1978 · External reference
10.1007/978-3-662-01593-3
10.1007/978-3-662-01593-3 · 1971 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates
10.1371/journal.pone.0192312 · 2018 · External reference
Safety and immunogenicity of heterologous and homologous 2-dose regimens of adenovirus serotype 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized, controlled phase 1 study
10.1093/infdis/jiaa586 · 2022 · External reference
Safety and immunogenicity of novel adenovirus type 26– and modified vaccinia Ankara–vectored Ebola vaccines: a randomized clinical trial
10.1001/jama.2016.4218 · 2016 · External reference
Unresolved reference
External reference
Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya
10.1093/infdis/jiz071 · 2019 · External reference
Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania
10.1093/infdis/jiz070 · 2019 · External reference
Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay
10.1016/j.jviromet.2018.02.018 · 2018 · External reference
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine
10.1172/jci60202 · 2012 · External reference
Unresolved reference
External reference
Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara–vectored Ebola vaccines at 1 year
10.1001/jama.2016.20644 · 2017 · External reference
Safety and long-term immunogenicity of the two-dose Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
10.1016/s1473-3099(21)00125-0 · 2022 · External reference
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
10.1016/s1473-3099(21)00128-6 · 2022 · External reference
Chimpanzee adenovirus vector Ebola vaccine
10.1056/nejmoa1410863 · 2017 · External reference
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
10.1016/j.vaccine.2010.10.037 · 2010 · External reference
Ebola and Marburg virus diseases in Africa: increased risk of outbreaks in previously unaffected areas?
10.1111/1348-0421.12181 · 2014 · External reference
Safety of combination vaccines: perception versus reality
10.1097/00006454-200111001-00007 · 2001 · External reference
Multivalent and multipathogen viral vector vaccines
10.1128/cvi.00298-16 · 2017 · External reference
